Haematology Oncology Oncology Medical Center

Lake Success, NY, United States

Haematology Oncology Oncology Medical Center

Lake Success, NY, United States
SEARCH FILTERS
Time filter
Source Type

Bosch R.,Biomedical Research Institute Sant Pau | Bosch R.,Autonomous University of Barcelona | Mora A.,Biomedical Research Institute Sant Pau | Mora A.,Autonomous University of Barcelona | And 21 more authors.
Leukemia and Lymphoma | Year: 2017

In normal B-cells, B-cell antigen receptor (BCR) signaling can be negatively regulated by the low-affinity receptor FcγRIIb (CD32b). To better understand the role of FcγRIIb in chronic lymphocytic leukemia (CLL), we correlated its expression on 155 samples from newly-diagnosed Binet A patients with clinical characteristics and outcome. FcγRIIb expression was similar in normal B-cells and leukemic cells, this being heterogenous among patients and within CLL clones. FcγRIIb expression did not correlate with well known prognostic markers [disease stage, serum beta-2 microglobulin (B2M), IGHV mutational status, expression of ZAP-70 and CD38, and cytogenetics] except for a weak concordance with CD49d. Moreover, patients with low FcγRIIb expression (69/155, 44.5%) required therapy earlier than those with high FcγRIIb expression (86/155, 55.5%) (median 151.4 months vs. not reached; p=.071). These results encourage further investigation on the role of FcγRIIb in CLL biology and prognostic significance in larger series of patients. © 2017 Informa UK Limited, trading as Taylor & Francis Group

Loading Haematology Oncology Oncology Medical Center collaborators
Loading Haematology Oncology Oncology Medical Center collaborators